CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Clinical Trials Arena
Original article

First patient dosed in Vial’s Phase Ib trial of IL-13 x TSLP antibody

Phase 1IL-13 x TSLPPositive
AI Analysis

Summary

Vial has dosed the first patient in a Phase Ib clinical trial of its IL-13 x TSLP bispecific antibody candidate for mild-to-moderate asthma.

Clinical Trial Data

Phase

Ib

Importance:3/10
Sentiment:
0.30
phase_ibasthmaantibodyfirst_patient_dosed
Related Companies

Read the original article

Published by Clinical Trials Arena on October 6, 2026 7:54 AM

Read Original